After first-line approval in DLBCL, debate continues around benefit from Roche's ADC Polivy
The FDA approved Roche and Genentech’s antibody-drug conjugate Polivy in April as a first-line treatment for diffuse large B-cell lymphoma (DLBCL) alongside a chemotherapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.